MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-03-2025
Solid Biosciences Total Current Liabilities 2011-2026 | SLDB
Annual Total Current Liabilities Solid Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.3 M | 14.5 M | 22.5 M | 23.6 M | 24.5 M | 18.3 M | 12.5 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.3 M | 12.5 M | 20.9 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M |  USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.05 | -3.24 % | $ 113 M |  Canada |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Evolus
EOLS
|
75.3 M | $ 5.74 | 2.59 % | $ 370 M | USA |
 |
China Pharma Holdings
CPHI
|
5.02 M | $ 0.54 | -7.57 % | $ 9.43 M |  China |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.54 | -3.54 % | $ 49.8 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Harrow Health
HROW
|
96.3 M | $ 36.19 | -7.73 % | $ 1.33 B | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.49 | -3.19 % | $ 435 M | USA |
 |
Assertio Holdings
ASRT
|
93.4 M | $ 11.96 | -0.89 % | $ 850 M | USA |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 5.56 | -1.24 % | $ 2.03 B | Canada |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.89 | 0.52 % | $ 381 M | USA |
 |
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | Canada |
 |
Perrigo Company plc
PRGO
|
1.01 B | $ 11.22 | -4.06 % | $ 1.55 B | USA |
 |
TherapeuticsMD
TXMD
|
6.85 M | $ 2.24 | 3.86 % | $ 23.4 M | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Veru
VERU
|
11.9 M | $ 2.53 | 0.8 % | $ 341 M | USA |
 |
Viatris
VTRS
|
6.75 B | $ 14.58 | -0.92 % | $ 17.5 B | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.69 | -10.34 % | $ 2.98 M | USA |
 |
Rockwell Medical
RMTI
|
16.6 M | $ 0.88 | -0.91 % | $ 20.5 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 22.78 | -0.35 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.45 | -6.81 % | $ 134 M | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 0.76 | -2.49 % | $ 37.9 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.66 | -5.0 % | $ 3.3 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
433 M | $ 7.07 | -3.15 % | $ 4.37 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |